Navigation Links
DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
Date:4/16/2008

t inhibitor of secretory phospholipase A2(sPLA2) activity, including groups IIA, V, and X. The U.S. Food and Drug Administration granted A-001 orphan drug status for the prevention of acute chest syndrome in patients with sickle cell disease in December 2007.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals is a privately-held company committed to developing and commercializing clinical pharmaceutical products that address unmet medical needs of patients with life-threatening, chronic and acute inflammatory diseases and autoimmune disorders. The Company has acquired from Eli Lilly and Company and Shionogi & Co., Ltd. worldwide rights (excluding Japan) to a series of clinical and pre-clinical compounds that inhibit the enzymatic activity of members of the phospholipase (PLA2) family - a group of enzymes responsible for the release of arachidonic acid and subsequent production of leukotrienes, prostacyclins and other mediators of inflammation. These highly potent compounds inhibit novel, upstream steps in the inflammation cascade and have the potential to address a variety of diseases. The company has also acquired exclusive and worldwide rights to a peptide fusion protein, A-623, for the treatment of systemic lupus erythematosus (SLE) and other autoimmune diseases from Amgen. For more information, please visit http://www.anthera.com.

MEDIA CONTACT:

Anne Bowdidge (650) 218-6900

pr@anthera.com


'/>"/>
SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Fifth DSMB Meeting Supports Neurobiological Technologies Continuation of Phase 3 Stroke Trials With Viprinex(TM) (ancrod)
2. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
3. DSMB Supports Continuation of Phase 3 AGENDA Trial of Genasense(R) in Advanced Melanoma
4. DSMB Again Supports Continuation of the Phase III Clinical Trial of Medidur(TM) FA for the Treatment of DME
5. Evanston Northwestern Healthcare Researchers Explain Effects of Large-Scale, Universal MRSA Surveillance Program That Supports Expanded Intervention
6. ACR Supports American Cancer Society Inclusion of CT Colonography (Virtual Colonoscopy) as Recommended Screening Tool for Colorectal Cancer in New Screening Guidelines
7. New Clinical Data Further Supports Chromium Picolinates Role in Enhancing Brain Activity in Older Adults
8. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
9. FDA Advisory Committee Supports Efficacy and Safety of Zyprexa(R) Long-Acting Injection (LAI) for Schizophrenia Treatment
10. Interim Analysis Supports Continuation of Cell Genesys VITAL-1 Phase 3 Clinical Trial of GVAX Immunotherapy for Prostate Cancer
11. Interim Safety Analysis Supports Continuation of Allos Therapeutics Pivotal Phase 2 PROPEL Trial of PDX in Patients with Peripheral T-cell Lymphoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Humberto C. Antunes,  Galderma  worldwide CEO, will receive a ... of Drugs in Dermatology (JDD) at the upcoming ... is January 17-20, 2014, at the Omni Orlando Resort at ChampionsGate ... The ODAC is a distinguished event that delivers a ...
(Date:1/15/2014)... MultiCell Technologies, Inc. (OTC Bulletin Board: MCET.OB ... composition of matter, biological targets, mechanism of action, methods ... This patent application describes a novel class ... which interfere with the basic homeostatic cellular processes in ...
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 2MultiCell Technologies Files Patent Application Covering New Class of RNA Therapeutics 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5
... (Nasdaq: SLTM ), a global leader in the ... the Tenth Annual JMP Securities Research Conference at the Ritz-Carlton ... pm Pacific Time. Stephen J. Fanning, Chairman, President and Chief ... corporate events. Attendance at this conference is by ...
... eResearchTechnology, Inc. (ERT), (Nasdaq: ERT ) ... medical devices to biopharmaceutical and healthcare organizations and ... efficacy services in drug development, announced today results ...  Unless otherwise noted, all comparative numbers refer to ...
Cached Medicine Technology:Solta Medical to Present at the JMP Securities Research Conference 2ERT Reports First Quarter 2011 Operating Results 2ERT Reports First Quarter 2011 Operating Results 3ERT Reports First Quarter 2011 Operating Results 4ERT Reports First Quarter 2011 Operating Results 5ERT Reports First Quarter 2011 Operating Results 6ERT Reports First Quarter 2011 Operating Results 7ERT Reports First Quarter 2011 Operating Results 8ERT Reports First Quarter 2011 Operating Results 9ERT Reports First Quarter 2011 Operating Results 10ERT Reports First Quarter 2011 Operating Results 11
(Date:4/24/2014)... BrainHealth will bring together national experts to discuss ... its inaugural Brain Health Summit, titled "The Human ... include Dr. Sandra Bond Chapman, founder and chief ... Chuck Grassley (R-IA), U.S. Representative Chaka Fattah (D-PA) ... and Early Learning, U.S. Department of Education. The ...
(Date:4/24/2014)... the relevance of palliation in advanced cancer are ... trials (RCTs). This is the result of an ... Efficiency in Health Care (IQWiG), which has now ... external experts, IQWiG analysed studies on four solid ... and pancreatic cancer. For this purpose, the research ...
(Date:4/24/2014)... is better to give than to receive at least ... study suggests. , The study found that 15- and 16-year-olds ... money to family members, are less likely to become depressed ... or keeping the money for themselves. , The researchers detail ... of Sciences . , The study focused on the ventral ...
(Date:4/24/2014)... CORVALLIS, Ore. An Oregon State University researcher has ... severity of the symptoms of autism spectrum disorder in ... the be the first to show a direct relationship ... of fine and gross motor skills should be included ... Megan MacDonald, an assistant professor in OSU,s College of ...
(Date:4/24/2014)... a scientist at the University of York reveals that ... development of the nervous system may also play a ... A research team, led by Dr Will Brackenbury, a ... at York, has studied how voltage-gated sodium channels assist ... found in the membranes of excitable cells, such as ...
Breaking Medicine News(10 mins):Health News:Inaugural Brain Health Summit focuses on brain resilience and regeneration 2Health News:Palliation is rarely a topic in studies on advanced cancer 2Health News:Palliation is rarely a topic in studies on advanced cancer 3Health News:Study: Altruistic adolescents less likely to become depressed 2Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Breast cancer replicates brain development process 2
... , , ... Corp., the leader in clinically proven brain fitness software, and ... collaboration to empower individuals with knowledge and tools that can ... this first-of-its-kind offer, consumers will have the opportunity to complement ...
... , , HOUSTON, Sept. ... that Dan Moore, President and Chief Executive Officer, and Greg Browne, ... Conference in New York on Tuesday, September 22, 2009 at 4:00 ... live and by replay at http://cc.talkpoint.com/ubsx001/092109a_ke/?entity=82_IT8KY1C . ...
... , PORTLAND, Maine, Sept. 10 ... Council for Disability Awareness (CDA) reveals a surge in the number ... , , The CDA,s 4(th) Annual Long-Term Disability ... identifies continuing and emerging disability trends among U.S. workers. Fifteen CDA ...
... STERIS Corporation (NYSE: STE ) today announced that the ... in New York on Tuesday, September 22, 2009. Michael J. ... p.m., Eastern time. , , The presentation can ... at www.steris-ir.com . The presentation will be ...
... ... Pioneer in the Development of Telehealth-Supported Solutions for Connected Care , ... Minneapolis, MN (PRWEB) September 10, 2009 ... Lenzmeier as chairman. Founded in 1993, ATI is the pioneer in the development and ...
... , , ANN ... biopharmaceutical company, today announced positive efficacy results from the second ... study for Ophena(TM) (ospemifene tablets), the company,s investigational ... (VVA). This study, together with the recent completion of ...
Cached Medicine News:Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 2Health News:Silicon Valley Firms Partner to Promote Brain and Body Awareness 3Health News:Cyberonics to Present at UBS Global Life Sciences Conference 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 2Health News:Disability Rates Continue Steady Climb, According to CDA's 2008 Disability Claims Review 3Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 2Health News:STERIS To Present at the UBS Global Life Sciences Conference on September 22, 2009 3Health News:Allen Lenzmeier Elected Chairman of the Board of Directors of American TeleCare, Inc. (ATI) 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 2Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 3Health News:QuatRx Announces Positive Results of Second Pivotal Phase 3 Clinical Study for Ophena(TM) (Ospemifene Tablets) in Treatment of Postmenopausal Vaginal Atrophy 4
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: